20200 427 Crop Curevac vaccines
C1
AV
excellent Research - federführende Forschung - Tübingen auf dem Berg - Nordstadt
°
- Max Planck Institute
- TTR Technologiezentrum Tübingen Reutlingen
- Sternwarte
- CureVac AG
Biotechnologieunternehmen
CureVac is a biopharmaceutical company headquartered in Tübingen, Germany, that develops therapies based on messenger RNA (mRNA).
The main research primarily focuses on cancer immunotherapies and prophylactic vaccines against infectious diseases
In September 2015, CureVac entered into a collaboration with the International AIDS Vaccine Initiative (IAVI) to accelerate the development of AIDS vaccines, utilizing immunogens developed by IAVI and partners, delivered via CureVac’s mRNA technology.
In November 2015, CureVac raised about $110 million (€100 million) in a private placement to enable expansion of its mRNA development platform and clinical-stage pipeline. CureVac also announced the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG). This new financing round was led by Baillie Gifford, adding to the approximately $220 million CureVac has raised since its founding in 2000. The new investors, Baillie Gifford, Chartwave Limited, Coppel Family, Northview and Sigma Group, join existing investors dievini Hopp BioTech holding GmbH & Co. KG of Dietmar Hopp and the Bill & Melinda Gates Foundation.
nur englisches wiki ist up to date
Bill & Melinda Gates-Stiftung: „Es geht uns nicht ums Geldverdienen“
Krebsimmuntherapie, et cetera, et cetera, et cetera.
et cetera - &c
(in English; /ɛtˈsɛtərə/; Latin pronunciation: [ɛt ˈkeːtɛra]) (rare: etceteros) (abbreviation: etc. or &c.)
etc.
Since inception, CureVac had received approximately $330 million (€300 million) in equity investments.
From Science to Patients – Ideas Become Treatments at CureVac
-
left to right
20200 427 Crop Curevac vaccines
C1
AV
excellent Research - federführende Forschung - Tübingen auf dem Berg - Nordstadt
°
- Max Planck Institute
- TTR Technologiezentrum Tübingen Reutlingen
- Sternwarte
- CureVac AG
Biotechnologieunternehmen
CureVac is a biopharmaceutical company headquartered in Tübingen, Germany, that develops therapies based on messenger RNA (mRNA).
The main research primarily focuses on cancer immunotherapies and prophylactic vaccines against infectious diseases
In September 2015, CureVac entered into a collaboration with the International AIDS Vaccine Initiative (IAVI) to accelerate the development of AIDS vaccines, utilizing immunogens developed by IAVI and partners, delivered via CureVac’s mRNA technology.
In November 2015, CureVac raised about $110 million (€100 million) in a private placement to enable expansion of its mRNA development platform and clinical-stage pipeline. CureVac also announced the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG). This new financing round was led by Baillie Gifford, adding to the approximately $220 million CureVac has raised since its founding in 2000. The new investors, Baillie Gifford, Chartwave Limited, Coppel Family, Northview and Sigma Group, join existing investors dievini Hopp BioTech holding GmbH & Co. KG of Dietmar Hopp and the Bill & Melinda Gates Foundation.
nur englisches wiki ist up to date
Bill & Melinda Gates-Stiftung: „Es geht uns nicht ums Geldverdienen“
Krebsimmuntherapie, et cetera, et cetera, et cetera.
et cetera - &c
(in English; /ɛtˈsɛtərə/; Latin pronunciation: [ɛt ˈkeːtɛra]) (rare: etceteros) (abbreviation: etc. or &c.)
etc.
Since inception, CureVac had received approximately $330 million (€300 million) in equity investments.
From Science to Patients – Ideas Become Treatments at CureVac
-
left to right